α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b

Science China Life Sciences

Volumn 54, Issue 1, 2011, Pages 39-47

  Ma, Hui ^a   Wang, Jiang Hua ^a   Guo, Fang ^a   Wei, Lai ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

chronic hepatitis B; pegylated interferon alfa 2b; 2 HS glycoprotein

Indexed keywords

EID: 78751677171     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-4111-4     Document Type: Article

References (29)

1. Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2007, 45: 507-539.
2. Liaw Y F, Tai D I, Chu C M, et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology, 1988, 8: 493-496.
3. De Jongh F E, Janssen H L, De Man R A, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology, 1992, 103: 1630-1635.
4. Fattovich G, Giustina G, Schalm S W, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology, 1995, 21: 77-82.
5. Samuel C E. Antiviral actions of interferons. Clin Microbiol Rev, 2001, 14: 778-809.
6. Levv D E, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev, 2001, 12: 143-156.
7. Biron C A. Interferons-a and -b as imune regulators: A new look. Immunity, 2001, 14: 661-664.
8. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur J Haematol, 1997, 59: 129-135.
9. Wong D K, Cheung A M, O'Rourke K, et al. Effect of alphainterferon in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med, 1993, 119: 312-323.
10. Janssen H L, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet, 2005, 365: 123-129.
11. Perrillo R P, Schiff E R, Davis G L, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med, 1990, 323: 295-301.
12. Lok A S, Wu P C, Lai C L, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology, 1992, 102: 2091-2097.
13. Feng J T, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene, 2006, 25: 3810-3817.
14. Poon T C, Hui A Y, Chan H L, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: A pilot study. Clin Chem, 2005, 51: 328-335.
15. Low T Y, Leow C K, Salto-Tellez M, et al. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics, 2004, 4: 3960-3974.
16. He Q Y, Lau G K, Zhou Y, et al. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics, 2003, 3: 666-674.
17. Parent R, Beretta L. Proteomics in the study of liver pathology. J Hepatol, 2005, 43: 177-183.
18. Lv S, Wei L, Wang J H, et al. Identification of novel molecular candidates for acute liver failure in plasma of BALB/c murine model. J Proteome Res, 2007, 6: 2746-2752.
19. Li C, Tan Y X, Zhou H, et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics, 2005, 5: 1125-1139.
20. Kim W, Oe L S, Kim J S, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res, 2003, 9: 5493-5500.
21. Hoofnagle J H, Schafritz D A, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology, 1987, 7: 758-763.
22. Hoofnagle J H. Chronic type B hepatitis. Gastroenterology, 1983, 84: 422-424.
23. Chu C M, Karayiannis P, Fowler M J, et al. Natural history of chronic hepatitis B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. Hepatology, 1985, 5: 431-434.
24. Srinivas P R, Wagner A S, Reddy L V, et al. Serum α-2-HSglycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol, 1993, 7: 1445-1455.
25. Kalabay L, Chavin K, Lebreton J P, et al. Human recombinant α-2-HS glycoprotein is produced in insect cells as a full-length inhibitor of the insulin receptor tyrosine kinase. Horm Metab Res, 1998, 30: 1-6.
26. Demetriou M, Binkert C, Sukhu B, et al. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem, 1996, 271: 12755-12761.
27. Ohnishi T, Nakamura O, Arakaki N, et al. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary cultures in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem, 1997, 243: 753-761.
28. Kalabay L, Jakab L, Prohászka Z, et al. Human fetuin/alpha-2-HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol, 2002, 14: 389-394.
29. Kalabay L, Gráf L, Vörös K, et al. Human serum fetuin A/alpha2HSglycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. BMC Gastroenterol, 2007, 7: 15.